# Encoded Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/encoded-therapeutics

- Industry: Biotechnology
- Headquarters: South San Francisco, US
- Website: www.encoded.com
- Total disclosed funding: $538M
- Latest round: Series F (Sep 9, 2026)
- Investors on record: 18

## About

Encoded Therapeutics, Inc. is a biotechnology company focused on developing genetic medicines for central nervous system disorders, utilizing innovative gene therapies to address significant health challenges.Encoded Therapeutics was founded in 2014 and is headquartered in South San Francisco, US. The company specializes in creating gene therapies for CNS disorders. The founders, Kartik Ramamoorthi and Stephanie Tagliatela, have backgrounds in biotechnology and pharmaceuticals. In September 2026, Encoded Therapeutics, Inc. raised USD 275 million in series F funding co-led by returning investor GV and an unspecified investor, with participation from other returning investors RTW Investments, ARCH Venture Partners, Farallon Capital Management, Illumina Ventures, Matrix Capital Management, Nolan Capital, SB Investment Advisers, and Venrock. New investors Braidwell, Invus Financial Advisors, and Janus Henderson Investors also participated in the round. Encoded Therapeutics specializes in developing genetic medicines aimed at addressing central nervous system (CNS) disorders, which contribute significantly to global morbidity and mortality. The company's core product offerings include novel gene therapies designed to target specific cell types with unique genetic profiles, enhancing specificity, selectivity, and potency compared to earlier therapies. Their flagship product, ETX101, targets Dravet Syndrome, a severe epilepsy form, aiming to provide long-lasting benefits for patients. Encoded Therapeutics collaborates with healthcare professionals, hospitals, and research institutions across North America and Europe.Encoded Therapeutics generates revenue through partnerships with healthcare institutions and pharmaceutical companies seeking innovative CNS therapies. Their B2B model includes collaborations with research organizations and hospitals for clinical trials and product development, which may involve licensing agreements that provide access to proprietary technologies. While specific pricing structures are not disclosed, the company likely uses value-based pricing models reflecting potential health benefits and cost savings from their advanced gene therapies. As clinical stages progress toward commercialization, these revenue channels are expected to expand significantly.Encoded Therapeutics aims to leverage the USD 125 mn raised during the Series D funding round to advance its pipeline of gene therapies, focusing on the clinical development of ETX101 and potentially other products targeting CNS disorders. The company will use the September 2026 funding to advance the development of precision genetic medicines for severe neurological disorders.

## Funding rounds

- Series F, Sep 9, 2026, $275M — ARCH Venture Partners, Venrock, GV, Janus Henderson Investors, Invus Financial Advisors, RTW Investments, Farallon Capital Management, Matrix Capital Management, Illumina Ventures, Nolan Capital, SB Investment Advisers, Braidwell
- Series D, Jul 22, 2020, $125M — ARCH Venture Partners, Menlo Ventures, Meritech Capital Partners, GV, RTW Investments, Farallon Capital Management, Matrix Capital Management, Boxer Capital, Illumina Ventures, SB Investment Advisers, HBM Genomics, Nolan Capital
- Series C, Jun 26, 2019, $104M — ARCH Venture Partners, Menlo Ventures, Venrock, Alexandria Venture Investments, Altitude Life Science Ventures, RTW Investments, Matrix Capital Management, Boxer Capital, Illumina Ventures
- Series B, Dec 28, 2016, $34M — ARCH Venture Partners, Altitude Life Science Ventures

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series B, Series C, Series D, Series F
- Altitude Life Science Ventures (https://capitalatlas.ai/funds/altitude-life-science-ventures) — Series B, Series C
- Menlo Ventures (https://capitalatlas.ai/funds/menlo-ventures) — Series C, Series D
- Venrock (https://capitalatlas.ai/funds/venrock) — Series C, Series F
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series C
- RTW Investments (https://capitalatlas.ai/funds/rtw-investments) — Series C, Series D, Series F
- Matrix Capital Management — Series C, Series D, Series F
- Boxer Capital (https://capitalatlas.ai/funds/boxer-capital) — Series C, Series D
- Illumina Ventures (https://capitalatlas.ai/funds/illumina-ventures) — Series C, Series D, Series F
- Meritech Capital Partners (https://capitalatlas.ai/funds/meritech-capital-partners) — Series D
- GV (https://capitalatlas.ai/funds/gv) — Series D, Series F
- Farallon Capital Management (https://capitalatlas.ai/funds/farallon-capital-management) — Series D, Series F
- SB Investment Advisers (https://capitalatlas.ai/funds/sb-investment-advisers) — Series D, Series F
- HBM Genomics (https://capitalatlas.ai/funds/hbm-genomics) — Series D
- Nolan Capital — Series D, Series F
- Janus Henderson Investors — Series F
- Invus Financial Advisors (https://capitalatlas.ai/funds/invus-financial-advisors) — Series F
- Braidwell (https://capitalatlas.ai/funds/braidwell) — Series F